



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/551,901	10/04/2005	Hiroshi Miura	277987US0PCT	6206
22850	7590	04/18/2008		
OBLON, SPIVAK, MCCLELLAND MAIER & NEUSTADT, P.C. 1940 DUKE STREET ALEXANDRIA, VA 22314			EXAMINER PALENIK, JEFFREY T	
			ART UNIT	PAPER NUMBER
			1615	
			NOTIFICATION DATE	DELIVERY MODE
			04/18/2008	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

patentdocket@oblon.com
oblonpat@oblon.com
jgardner@oblon.com

Office Action Summary	Application No. 10/551,901	Applicant(s) MIURA ET AL.	
	Examiner Jeffrey T. Palenik	Art Unit 1615	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 26 March 2008.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-13 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-13 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date <u>4 Oct 2005, 3 Jan 2006 and 26 Sept 2007</u> . | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Response to Remarks

Applicant's election **without traverse** of Group I, claims 1-13, in the reply filed on 26 March 2008 is acknowledged.

Claims 14-23 are hereby withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made **without traverse** in the reply filed on 26 March 2008.

The remaining claims 1-13 are presented and represent all claims under consideration.

Information Disclosure Statement

Three Information Disclosure Statements filed 4 October 2005, 3 January 2006 and 26 September 2007 are acknowledged and have been reviewed.

Claim Objections

Claims 8-13 are objected to under 37 CFR 1.75(c) as being in improper form because a multiple dependent claim should refer to other claims in the alternative only and/or cannot depend from any other multiple dependent claims. See MPEP § 608.01(n). Accordingly, the claims have not been further treated on the merits.

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection

Art Unit: 1615

is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 1-13 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 21-24 of copending Application No. 10/554,921. Although the conflicting claims are not identical, they are not patentably distinct from each other because claim 21 of the '921 application, like claim 1 of the instant application, is drawn to a composition comprising an extremely poorly (e.g. very low) water-soluble drug. Both the claims are drawn only to the composition since the language in both claims reflects "product-by-process" language (see MPEP 2113). Co-pending claim 22 recites a range for the specific surface area which anticipates that which is recited in the instant claim 8. Instant claim 11 and co-pending claim 23 recite the same ratio of porous material to drug. Instant claim 12 and co-pending claim 24 both recite the compound 2-benzyl-5-(4-chlorophenyl)-6-[4-(methylthio)phenyl]-2H-pyridazin-3-one.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claim 1-13 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

The metes and bounds of the limitations cited in the instant claims 1 and 4 are unclear with regards to the material used. The instant claim 1 recites that the porous material is “exclusive of a silica material” whereas claim 4 recites further limitations to the porous silicon material as including both silicon dioxide and hydrated silicon dioxide. The term “silica” is a well known chemical synonym for silicon dioxide, whether it is hydrated or not. As such, the claims are rendered indefinite as it is unclear whether porous silica or silicon dioxide material is included in the instant invention. For the purposes of examination on the merits, the Examiner broadly and reasonably interprets the composition of the instant claims 1 and 4 as including porous silica material.

The term "very low" in claims 1-12, is a relative term which renders the claims indefinite. The term "extremely poorly" is not defined by the claim, the specification does not provide a standard for ascertaining the requisite degree, and one of ordinary skill in the art would not be reasonably apprised of the scope of the invention. The limitation rendered indefinite by the use of the above term, within the claim, is the degree of solubility of the drug. Given its broadest reasonable interpretation and for the purposes of examination on the merits, the limitation “very low water-soluble drug” is interpreted by the Examiner to mean “hydrophobic drug.”

The remaining claim 13 is rejected as being dependent from any one of the claims 1 to 12.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-13 are rejected under 35 U.S.C. 102(b) as being anticipated by Ohkuchi et al. (U.S. Patent 6,348,468).

The instant claims 1-11 are drawn to a composition comprising a hydrophobic drug. Per MPEP 2113, the recited claim language “produced by treating...” defines the claim as a product-by-process claim. As such, the instant claim 1 is interpreted by the Examiner to read only on the composition which is obtained (i.e. composition comprising a hydrophobic drug) regardless of the means through which it is obtained. Dependent claims 2-11 all recite limitations to the porous material associated with the process limitations of the instant claim 1 and *not* the resulting product or composition portion of the claim. As such, claims 2-11 are interpreted by the Examiner as reading on the same composition of claim 1. Dependent claim 12 further limits the hydrophobic drug of claim 1, to either 2-benzyl-5-(4-chlorophenyl)-6-[4-(methylthio)phenyl]-2H-pyridazin-3-one or prednisolone valerate acetate. Independent claim 13 recites a drug product composition containing a hydrophobic drug.

Art Unit: 1615

Ohkuchi et al. teaches in claim 8 a pharmaceutical composition comprising the hydrophobic compound: 5-(4-chlorophenyl)-6-(4-methylthiophenyl)-2-benzyl-2H-pyridazin-3-one.

Claims 1-13 are rejected under 35 U.S.C. 102(b) as being anticipated by Yamamoto et al. (U.S. Patent 5,236,906).

The instant claims 1-13 are drawn to a composition comprising a hydrophobic drug, as described above. Dependent claim 12 recites prednisolone valerate acetate as an alternative hydrophobic drug limitation to the composition of claim 1.

Yamamoto et al. teaches a topical dermatological composition consisting essentially of an adrenocortical hormone which may be further selected from a specific group including prednisolone valerate acetate (claim 1).

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.

Art Unit: 1615

2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

Claims 1-11 and 13 are rejected under 35 U.S.C. 103(a) as being unpatentable over Tsutomu et al. JP-2002-345940 (machine translation) in view of JP 61-227520.

The instant claims are drawn to a composition comprising a hydrophobic drug, as described above.

Tsutomu et al. teach a sustained release material, treated (e.g. constituted) through supercritical or subcritical fluid, which is released from a porous material (claim 1). Woody material (claim 1) reads on porous carbon material of the instant claim 2. Claims 3-5 teaches a porous silica body, which carries a sustained release material (e.g. an oil), which has been contacted by either a supercritical or subcritical fluid. Said fluid is taught as being carbon dioxide (claim 7).

Tsutomu teaches neither the ratio of the porous material to hydrophobic drug nor the specific surface area of the porous material(s), as claimed by Applicants.

JP 61-227520 suggests a plurality of different porous materials having the pores filled with drugs.

It would have been obvious to a person having ordinary skill in the art at the time the inventions was made to have employed the process of Tsutomu et al. with the porous materials taught by JP 61-227520.

Since the values of each parameter with respect to the claimed composition is adjustable, it follows that each is a result-effective parameter that a person having ordinary skill in the art would routinely optimize. Optimization of parameters is a routine practice that would be

Art Unit: 1615

obvious for a person of ordinary skill in the art to employ. It would have been customary for an artisan of ordinary skill to determine the optimal manufacturing method (e.g. ratio of porous silica material to hydrophobic drug and/or specific surface area of the porous silica material) in order to best achieve the desired results. Thus, absent some demonstration of unexpected results from the claimed parameters, optimization of any of these parameters would have been obvious at the time of Applicant's invention.

Claims 1-13 are rejected under 35 U.S.C. 103(a) as being unpatentable over Ohkuchi et al. (U.S. Patent 6,348,468) in further view of defined products available from Sigma-Aldrich.

The instant claims are drawn to a composition comprising a hydrophobic drug, as described above.

Ohkuchi et al. teaches mixing the compound 5-(4-chlorophenyl)-6-(4-methylthiophenyl)-2-benzyl-2H-pyridazin-3-one, with porous silicon material (e.g. porous silica gel material). The mixing occurs by virtue of purifying the compound over a silica gel chromatography column. Ohkuchi teaches neither the ratio of the porous silica material to hydrophobic drug nor the specific surface area of the porous silica material, as claimed by Applicants. Since the values of each parameter with respect to the claimed composition is adjustable, it follows that each is a result-effective parameter that a person having ordinary skill in the art would routinely optimize. Optimization of parameters is a routine practice that would be obvious for a person of ordinary skill in the art to employ. It would have been customary for an artisan of ordinary skill to acquire silica gel column chromatography material having the requisite pore diameter (e.g. between 1-20 nm) and specific surface area (e.g. between 100-2,000 m²/g) in addition to

Art Unit: 1615

determining the optimal manufacturing method (e.g. ratio of porous silica material to hydrophobic drug) and/or specific surface area of the porous silica material) in order to best achieve the desired results (see Sigma-Aldrich silica gel product #403653). Thus, absent some demonstration of unexpected results from the claimed parameters, optimization of any of these parameters would have been obvious at the time of Applicant's invention.

No claims allowed.

Correspondence

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jeffrey T. Palenik whose telephone number is (571) 270-1966. The examiner can normally be reached on 7:30 am - 5:00 pm; M-F (EST).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Woodward can be reached on (571) 272-8373. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR

Art Unit: 1615

system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Jeffrey T. Palenik/
Examiner, Art Unit 1615

/Michael P Woodward/
Supervisory Patent Examiner, Art Unit 1615